Generic name: canagliflozin 100mg
Dosage form: tablet, film coated
Medically reviewed by Drugs.com. Last updated on May 15, 2019.
Prior to Initiation of INVOKANA
Assess renal function before initiating INVOKANA and periodically thereafter [see Warnings and Precautions (5.4)].
In patients with volume depletion not previously treated with canagliflozin, normalize volume status before initiating INVOKANA [see Warnings and Precautions (5.2), Use in Specific Populations (8.5, 8.6)].
The recommended starting dose of INVOKANA (canagliflozin) is 100 mg once daily, taken before the first meal of the day. In patients tolerating INVOKANA 100 mg once daily who have an eGFR of 60 mL/min/1.73 m2 or greater and require additional glycemic control, the dose can be increased to 300 mg once daily [see Dosage and Administration (2.3), Clinical Pharmacology (12.3), and Patient Counseling Information (17)].
Patients with Renal Impairment
The dose of INVOKANA is limited to 100 mg once daily in patients with moderate renal impairment with an eGFR of 45 to less than 60 mL/min/1.73 m2.
Initiation of INVOKANA is not recommended in patients with an eGFR less than 45 mL/min/1.73 m2.
INVOKANA is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m2 [see Contraindications (4)].
Concomitant Use with UDP-Glucuronosyl Transferase (UGT) Enzyme Inducers
If an inducer of UGTs (e.g., rifampin, phenytoin, phenobarbital, ritonavir) is co-administered with INVOKANA, consider increasing the dosage to 300 mg once daily in patients currently tolerating INVOKANA 100 mg once daily who have an eGFR of 60 mL/min/1.73 m2 or greater and require additional glycemic control [see Drug Interactions (7.1)].
Consider another antihyperglycemic agent in patients with an eGFR of 45 to less than 60 mL/min/1.73 m2 receiving concurrent therapy with a UGT inducer.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Invokana (canagliflozin)
- Side Effects
- During Pregnancy
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 242 Reviews
- Drug class: SGLT-2 inhibitors
- FDA Alerts (6)
- FDA Approval History